A Prospective Non-interventional Multicentre Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms EUREKA
- Sponsors AbbVie
- 10 Jun 2017 Biomarkers information updated
- 30 May 2017 Planned End Date changed from 1 Apr 2018 to 30 Jul 2018.
- 30 May 2017 Planned primary completion date changed from 1 Apr 2018 to 30 Jul 2018.